Cardiology_Cardiovascular_Disease

2017 ACC/AHA Hypertension Guidelines: The TakeawaysClick through our topline review of the key takeaways from this long-awaited update.
The Top 5 Biomarkers in Cardiovascular Disease PreventionWhich biomarker is most useful in what situation? Find out how one cardiologist makes these decisions. Do you concur?
Can Follow-up Hemodynamic Variables Predict Outcome in PAH?Results of a new study suggest that stroke volume index may be the better hemodynamic variable to monitor in PAH – not cardiac index.
5 Stubborn Statin Myths vs Data that Refute ThemAt AHA.17, Dr Rory Collins offered large-scale trial data to help dispel dangerous disinformation still circulating about the effects of statins.
2017 ACC/AHA Hypertension Guidelines: Case StudyClick through this short case study for an illustration of the key principles put forth in the revised ACC/AHA guidelines on hypertension diagnosis and management.
Cardiologists Talk Concrete Application of Artificial IntelligenceTwo cardiologists respected for their technological expertise took the concept of AI from blue sky to concrete clinical examples at AHA 2017.
New 2017 ACC/AHA Hypertension Guidelines, At-a-GlanceA shift to earlier intervention and emphasis on basics like proper BP measurement and intensive lifestyle change are the key revisions.
Selexipag Delays PAH Progression in Patients with Connective Tissue DiseaseResults of a subgroup analysis from the GRIPHON trial are promising for a hard-to-treat population.
New Biomarker Could Improve ARDS, AHF DiagnosisA biomarker of myocardial strain and inflammation may be able to discriminate between two similar pulmonary emergencies.
Methamphetamine-associated PAH: First Prospective Cohort StudyMethamphetamine abuse is on a steady rise in the US. A new study highlights the nature and dangers of Meth-PAH.